Cardiac Amyloidosis clinical trials

Explore recruiting cardiac amyloidosis clinical trials.

Recruiting cardiac amyloidosis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Cardiac Amyloidosis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Prospective, monocentric, exploratory phase II study for the evaluation of the diagnostic use of the tracer PET (18F) -Flutemetamol (Vizamyl®) in patients with cardiac amyloidosis

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

An open-label, multi-center, non-randomized pivotal Phase 3 study to evaluate the efficacy and safety of [18F]florbetaben Positron Emission Tomography (PET) imaging to diagnose cardiac AL amyloidosis

Spain, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Patisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)

Denmark, Belgium, Italy, Sweden, Czechia, Netherlands +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A multi-center phase 3 study of 18F-florbetaben positron emission tomography/computed tomography (PET-CT) to non-invasively diagnose cardiac AL amyloidosis: the PETAL study.

Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

HeArt Rate and quality of Life in transthyrEtin cardiac amYloidosis (HARLEY)

Italy

Therapeutic use (Phase IV) EU CTIS Study details

Effect of dapagliflozin on the quality of life and exercise capacity of patients with amyloid transthyretin cardiac amyloidosis: a pilot, phase 2b study

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Cardiac Amyloidosis trials by city

Cardiac Amyloidosis in Toronto Cardiac Amyloidosis in Vancouver Cardiac Amyloidosis in Montreal Cardiac Amyloidosis in Calgary Cardiac Amyloidosis in Edmonton Cardiac Amyloidosis in Ottawa Cardiac Amyloidosis in Winnipeg Cardiac Amyloidosis in Quebec City Cardiac Amyloidosis in Hamilton Cardiac Amyloidosis in Kitchener Cardiac Amyloidosis in London Cardiac Amyloidosis in Halifax Cardiac Amyloidosis in New York Cardiac Amyloidosis in Los Angeles Cardiac Amyloidosis in Chicago Cardiac Amyloidosis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease